Validation of stage groupings in the eighth edition of the tumor node metastasis classification for lung adenocarcinoma

被引:7
作者
Yu, Wenguan [1 ]
Zhao, Qingchun [1 ]
Xia, Chunqiu [1 ]
Dong, Ming [1 ]
Liu, Jinghao [1 ]
Li, Xin [1 ]
Zhao, Honglin [1 ]
Chen, Gang [1 ]
Liu, Hongyu [1 ]
Chen, Jun [1 ]
机构
[1] Tianjin Med Univ, Gen Hosp, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin Lung Canc Inst,Dept Lung Canc Surg, Anshan Rd 154, Tianjin 300052, Peoples R China
基金
中国国家自然科学基金;
关键词
EGFR gene mutation; lung adenocarcinoma; thoracic surgery; TNM classification; GROUND-GLASS OPACITY; IASLC/ATS/ERS CLASSIFICATION; INTERNATIONAL-ASSOCIATION; HISTOLOGICAL SUBTYPES; LIMITED RESECTION; OPEN-LABEL; PHASE-II; CANCER; EGFR; GEFITINIB;
D O I
10.1111/1759-7714.12961
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The purpose of this study was to validate stage groupings in the 8th edition of the tumor node metastasis (TNM) classification for lung adenocarcinoma and explore the non-anatomic factors that influence the prognosis of lung adenocarcinoma patients in China. Methods We retrospectively analyzed the data of 291 lung adenocarcinoma patients at our department between 2008 and 2013. Logrank tests and Cox regression models were used to analyze survival among adjacent stage groupings. Kaplan-Meier curves were used to estimate overall survival (OS). Results There were significant differences in OS in adjacent stage groupings in early stages in the 8th edition. There were also significant differences between patients treated with radical surgery and limited resection (P = 0.027). Lepidic predominant adenocarcinoma (LPA) had better survival rates than acinar predominant (APA), papillary predominant, and solid predominant with mucin production adenocarcinoma (SPA) (P = 0.008). Survival rates of micropapillary predominant adenocarcinoma were lower than the others (P = 0.003). EGFR mutations were closely associated with lepidic predominant (65%, P = 0.56) but less commonly associated with solid predominant with mucin production adenocarcinoma (24%, P = 0.02). There was no significant difference in survival between EGFR gene mutation-positive and negative groups (P = 0.402). Conclusion The 8th edition TNM may be more accurate and applicable than the 7th edition for Chinese lung adenocarcinoma patients who have undergone surgical treatment. Stage IV patients may gain survival improvement from radical surgery.
引用
收藏
页码:483 / 491
页数:9
相关论文
共 30 条
  • [1] Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?
    Bauml, Joshua
    Mick, Rosemarie
    Zhang, Yu
    Watt, Christopher D.
    Vachani, Anil
    Aggarvval, Charu
    Evans, Tracey
    Langer, Corey
    [J]. LUNG CANCER, 2013, 81 (03) : 347 - 353
  • [2] Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease
    Campos-Parra, Alma D.
    Aviles, Alejandro
    Contreras-Reyes, Susana
    Rojas-Marin, Carlos E.
    Sanchez-Reyes, Roberto
    Borbolla-Escoboza, Rafael J.
    Arrieta, Oscar
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (05) : 1439 - 1447
  • [3] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [4] Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naive non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR
    Choi, Yoon Ji
    Lee, Dae Ho
    Choi, Chang Min
    Lee, Jung Shin
    Lee, Seung Jin
    Ahn, Jin-Hee
    Kim, Sang-We
    [J]. BMC CANCER, 2015, 15
  • [5] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
    Cross, Darren A. E.
    Ashton, Susan E.
    Ghiorghiu, Serban
    Eberlein, Cath
    Nebhan, Caroline A.
    Spitzler, Paula J.
    Orme, Jonathon P.
    Finlay, M. Raymond V.
    Ward, Richard A.
    Mellor, Martine J.
    Hughes, Gareth
    Rahi, Amar
    Jacobs, Vivien N.
    Brewer, Monica Red
    Ichihara, Eiki
    Sun, Jing
    Jin, Hailing
    Ballard, Peter
    Al-Kadhimi, Katherine
    Rowlinson, Rachel
    Klinowska, Teresa
    Richmond, Graham H. P.
    Cantarini, Mireille
    Kim, Dong-Wan
    Ranson, Malcolm R.
    Pao, William
    [J]. CANCER DISCOVERY, 2014, 4 (09) : 1046 - 1061
  • [6] Extended surgery for T4 lung cancer: a 30 years' experience
    Dartevelle, P. G.
    Mitilian, D.
    Fadel, E.
    [J]. GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2017, 65 (06) : 321 - 328
  • [7] International lung cancer trends by histologic type:: male:female differences diminishing and adenocarcinoma rates rising
    Devesa, SS
    Bray, F
    Vizcaino, AP
    Parkin, DM
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (02) : 294 - 299
  • [8] Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
    Fukuoka, Masahiro
    Wu, Yi-Long
    Thongprasert, Sumitra
    Sunpaweravong, Patrapim
    Leong, Swan-Swan
    Sriuranpong, Virote
    Chao, Tsu-Yi
    Nakagawa, Kazuhiko
    Chu, Da-Tong
    Saijo, Nagahiro
    Duffield, Emma L.
    Rukazenkov, Yuri
    Speake, Georgina
    Jiang, Haiyi
    Armour, Alison A.
    To, Ka-Fai
    Yang, James Chih-Hsin
    Mok, Tony S. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) : 2866 - 2874
  • [9] The clinicopathological and prognostic features of Chinese and Japanese inpatients with lung cancer
    Gao, Yang
    Zhang, Ji-feng
    Li, Qing-chang
    Liu, Jia-jie
    Liu, Li-li
    Yang, Xue-feng
    Jiang, Hua-mao
    Zheng, Hua-chuan
    [J]. ONCOTARGET, 2016, 7 (41) : 67425 - 67434
  • [10] Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma
    Gu, Jie
    Lu, Chunlai
    Guo, Jing
    Chen, Lingli
    Chu, Yiwei
    Ji, Yuan
    Ge, Di
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (05) : 474 - 480